Insight Molecular Diagnostics Balans Gezondheid
Financiële gezondheid criteriumcontroles 1/6
Insight Molecular Diagnostics heeft een totaal eigen vermogen van $-21.3M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $29.4M en $50.7M.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$17.76m |
| Aandelen | -US$21.30m |
| Totaal verplichtingen | US$50.74m |
| Totaal activa | US$29.44m |
Recente financiële gezondheidsupdates
Analyse-artikel • Sep 02
Here's Why We're A Bit Worried About Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analyse-artikel • May 15
We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyse-artikel • Nov 12
We Think Insight Molecular Diagnostics (NASDAQ:IMDX) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, Insight...Recent updates
Analyse-artikel • Sep 02
Here's Why We're A Bit Worried About Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Narratiefupdate • Jul 08
IMDX: Clinical Data And Registry Validation Will Support Higher Future Returns
Analysts have raised their fair value estimate for Insight Molecular Diagnostics from $9.00 to $12.00, citing updated assumptions around revenue growth, profit margins, and a lower projected future P/E multiple. What’s in the News for Insight Molecular Diagnostics Insight Molecular Diagnostics reported an online publication in Clinical Chemistry highlighting high concordance between its digital PCR based GraftAssure transplant monitoring test and a next generation sequencing assay for donor derived cell free DNA in kidney transplant patients, with agreement of 99.2% at the 0.5% dd cfDNA threshold.
Narratiefupdate • Jun 24
IMDX: FDA Review And New Transplant Data Will Drive Bullish Repricing
Analysts have adjusted their price target for Insight Molecular Diagnostics to $8.33. This reflects updated assumptions on the discount rate, profit margin, and future P/E, while keeping the fair value estimate unchanged at $8.33.Narratiefupdate • Jun 06
IMDX: FDA Review Of Transplant Rejection Test Will Drive Bullish Repricing
Analysts have adjusted their price target for Insight Molecular Diagnostics from $10.50 to about $8.33, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Insight Molecular Diagnostics submitted its GraftAssureDx donor derived cell free DNA (dd cfDNA) assay kit to the FDA for regulatory review, following 12 years of clinical development and three years of focused product work.Analyse-artikel • May 15
We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Narratiefupdate • May 15
IMDX: FDA Submission And Strengthened Cash Position Will Drive Bullish Repricing
Insight Molecular Diagnostics' analyst price target has moved from $8 to $12, with analysts pointing to secured funding from the recent $26M offering and the anticipated FDA submission for GraftAssureDx as key factors supporting this revision. Analyst Commentary Bullish Takeaways Bullish analysts view the move to a US$12 price target as reflecting reduced funding risk after the recent US$26M offering, which they see as supportive for execution on pending milestones.Narratiefupdate • Apr 28
IMDX: Upcoming FDA Review And Cash Cushion May Support Bullish Repricing
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing the recently completed $26M offering, which secures cash beyond a potential GraftAssureDx approval and an expected FDA submission in the coming weeks, as key drivers of their updated view. Analyst Commentary Bullish Takeaways Bullish analysts view the new $12 price target as reflecting improved funding visibility, with the recent $26M offering seen as supportive of ongoing operations past a potential GraftAssureDx approval.Narratiefupdate • Apr 13
IMDX: Upcoming FDA Submission And Cash Runway May Support Bullish Repricing
Analysts have raised their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26M capital raise and expectations around an upcoming FDA submission for GraftAssureDx as key supports for the new outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a US$12 price target as reflecting higher confidence that the recent US$26M capital raise supports the company through key regulatory milestones.Narratiefupdate • Mar 29
IMDX: Upcoming FDA Review And Capital Raise Will Support Bullish Repricing
Analysts have raised their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26,000,000 capital raise and the expected FDA submission for GraftAssureDx in the coming weeks as key factors supporting the revised target. Analyst Commentary Recent research updates give you a clearer picture of how the Street is reacting to Insight Molecular Diagnostics after its latest funding and upcoming regulatory milestones.Narratiefupdate • Mar 12
IMDX: Upcoming FDA Submission And Capital Raise Will Drive Bullish Repricing
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26m capital raise and expectations for an upcoming FDA submission for GraftAssureDx as key supports for the updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the move in the price target to $12 as reflecting higher confidence that the recent $26m capital raise supports the company through key regulatory milestones.Narratiefupdate • Feb 26
IMDX: Funding And Upcoming FDA Submission Will Shape Potential Upside
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing secured funding from the recent $26M offering and the anticipated FDA submission for GraftAssureDx as key supports for their updated view. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a $12 price target as reflecting higher conviction that the current funding and product plan can support the company through key milestones.Narratiefupdate • Feb 11
IMDX: Stable Outlook As Regulatory And Transplant Center Expansion Will Shape Upside
Analysts have adjusted their price target on Insight Molecular Diagnostics to reflect an updated fair value of $7.00 per share, a higher assumed future P/E of 121.71, and revised views on the discount rate and profit margin potential. What's in the News Year-end business update outlined commercial progress and the clinical trial status of the GraftAssureDx test kit, including preparation for an in vitro diagnostic de novo submission to the US Food & Drug Administration (FDA).Narratiefupdate • Jan 27
IMDX: Stable Outlook As Regulatory Progress And Transplant Testing Portfolio Will Shape Upside
Analysts have nudged their price target on Insight Molecular Diagnostics higher to reflect slightly refined assumptions on discount rate, profit margin and forward P/E. The updated target is now framed around a fair value of 7.0. What's in the News Year end business update outlines commercial progress for the GraftAssureDx test kit, including clinical trial status and plans for an in vitro diagnostic de novo submission to the United States Food & Drug Administration, alongside additional regulatory submissions and registry study work expected in 2026 (company update).Narratiefupdate • Jan 12
IMDX: Stable Outlook As Transplant Monitoring Pipeline And Regulatory Progress Will Support Upside
Narrative Update on Insight Molecular Diagnostics Analysts have slightly adjusted their price target on Insight Molecular Diagnostics, with the change reflecting updated fair value modeling around a 7.0% discount rate, approximately 41% revenue growth assumptions, a 16.24% profit margin, and a forward P/E near 120x. What's in the News Year end business update provided on commercial progress, including the GraftAssureDx test kit clinical trial and plans for an in vitro diagnostic de novo submission to the US Food & Drug Administration, alongside additional regulatory submissions and registry study work expected in 2026.Narratiefupdate • Dec 25
IMDX: Transplant Monitoring Expansion Will Drive Future Market Leadership
Analysts have modestly raised their price target on Insight Molecular Diagnostics to reflect incremental improvements in long term profit margin assumptions and a slightly lower discount rate, while maintaining broadly consistent growth expectations and valuation multiples. What's in the News Publication of a case study in the American Journal of Transplantation highlighted Insight Molecular Diagnostics' GraftAssure assay as essential for monitoring a high risk kidney transplant patient undergoing novel CD19 CAR T therapy without traditional immunosuppression (Key Developments).Narratiefupdate • Dec 11
IMDX: Transplant Monitoring Advances Will Drive Future Market Momentum
Narrative Update on Insight Molecular Diagnostics The analyst price target for Insight Molecular Diagnostics has been modestly revised upward by analysts, reflecting slightly higher fair value estimates supported by incremental improvements in projected discount rate, revenue growth, profit margin, and future price to earnings assumptions. What's in the News A published clinical study in the American Journal of Transplantation highlighted the GraftAssure assay as critical for long-term monitoring of a high-risk kidney transplant patient treated with novel CD19 CAR T therapy, confirming absence of rejection during cancer treatment (American Journal of Transplantation).Narratiefupdate • Nov 27
IMDX: Expanding Clinical Trial Participation Will Drive Market Momentum
Analysts have raised their price target for Insight Molecular Diagnostics from $6.13 to $7.00 per share, citing stronger expected revenue growth and improving profit margins in their updated forecasts. What's in the News Insight Molecular Diagnostics published results showing their GraftAssure assay enabled long-term non-immunosuppressed kidney transplant survival with no rejection, following CD19 CAR-T therapy in a complex patient case (study published in the American Journal of Transplantation).Seeking Alpha • Nov 14
Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating
Summary Initiating coverage of Insight Molecular Diagnostics Inc. with a Hold rating due to upcoming catalysts and pending FDA submission for GraftAssureDx kidney transplant assay. IMDX's decentralized GraftAssureDx aims to disrupt the $1B+ transplant rejection testing market, offering cost-effective, localized testing versus centralized lab competitors. Key risks include clinical validation, regulatory approval uncertainty, software readiness, potential FDA delays, and a limited cash runway likely requiring further capital raises. Applying a Hold rating as IMDX advances toward FDA filing by end-2025 and eyes expansion into heart and lung transplant assays in 2026 and 2027. Read the full article on Seeking AlphaAnalyse-artikel • Nov 12
We Think Insight Molecular Diagnostics (NASDAQ:IMDX) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, Insight...Narratiefupdate • Nov 12
IMDX: Increased Discount Rate Will Raise Uncertainty for Share Performance
Analysts have raised their price target for Insight Molecular Diagnostics from $5.42 to $6.13, citing improved revenue growth forecasts and higher profit margins as key factors contributing to the increased valuation. What's in the News Insight Molecular Diagnostics published study results in the American Journal of Transplantation, demonstrating the value of its GraftAssure assay for monitoring kidney transplant patients with severe complications.
Nieuw narratief • Apr 13
GraftAssure Assay Submissions Will Unlock Transplant Center Opportunities
Strategic partnerships and anticipated regulatory approvals are poised to significantly expand OncoCyte's market reach, boosting revenue and supporting scalability.Analyse van de financiële positie
Kortlopende schulden: IMDX heeft een negatief eigen vermogen, wat een ernstiger situatie is dan dat kortetermijnactiva de kortetermijnschulden niet dekken.
Langlopende schulden: IMDX heeft een negatief eigen vermogen, wat een ernstiger situatie is dan wanneer de kortetermijnactiva de langetermijnschulden niet dekken.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: IMDX is schuldenvrij.
Schuld verminderen: IMDX heeft een negatief eigen vermogen, dus we hoeven niet te controleren of de schuld in de loop van de tijd is afgenomen.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: IMDX heeft minder dan een jaar aan cash runway op basis van de huidige vrije kasstroom.
Voorspelling contante baan: IMDX heeft minder dan een jaar aan kasmiddelen beschikbaar als de vrije kasstroom blijft groeien met een historisch percentage van 6.4 % per jaar.
Ontdek gezonde bedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/09 13:08 |
| Aandelenkoers aan het einde van de dag | 2026/09/09 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Insight Molecular Diagnostics Inc. wordt gevolgd door 9 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| null null | KeyBanc Capital Markets Inc. |